Inflammation Research

, Volume 62, Issue 6, pp 581–587 | Cite as

Effect of chlorogenic acid on LPS-induced proinflammatory signaling in hepatic stellate cells

  • Haitao Shi
  • Lei Dong
  • Xiaoyan Dang
  • Yaping Liu
  • Jiong Jiang
  • Yan Wang
  • Xiaolan Lu
  • Xiaoyan Guo
Original Research Paper


Objective and design

This study was aimed at investigating the effect of chlorogenic acid (CGA) on lipopolysaccharide (LPS)-induced proinflammatory signaling in hepatic stellate cells (HSCs).


An immortalized rat HSC line was cultured in vitro and treated with LPS in the absence or presence of CGA. Reactive oxygen species (ROS) production in the HSCs was monitored by flow cytometer using DCFH-DA. The protein expression levels of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), nuclear factor-κB (NF-κB), and p-IκB-α were determined by Western blot. The mRNA expression levels of TLR4, MyD88, monocyte chemotactic protein 1(MCP-1), and interleukin 6 (IL-6) were detected by RT-PCR. The levels of MCP-1 and IL-6 in the culture supernatant of HSCs were measured by ELISA.


CGA had no effect on expression of TLR4 and MyD88. However, the treatment of CGA can inhibit LPS-induced production of ROS in HSCs. Meanwhile, CGA can inhibit LPS-induced nuclear translocation of NF-κB and IκB-α phosphorylation in HSCs, as well as NAC (a ROS scavenger). The mRNA expression and the levels of MCP-1 and IL-6 in the culture supernatant of the HSCs in this study were elevated by LPS stimulation and inhibited by CGA treatment, as well as NAC and PDTC (a NF-κB inhibitor).


Our results indicate that CGA can efficiently inhibit LPS-induced proinflammatory responses in HSCs and the anti-inflammatory effect may be due to the inhibition of LPS/ROS/NF-κB signaling pathway.


Chlorogenic acid LPS Inflammation 



Chlorogenic acid




Hepatic stellate cells


Toll-like receptor 4


Reactive oxygen species




Pyrrolidine dithiocarbamate



This work was supported by the National Natural Science Foundation of China (NO.81200310). The authors thank Hao Sun and Huaijie Wang for their language and writing assistance.


  1. 1.
    Bataller R, Brenner DA. Liver fibrosis. J Clin Investig. 2005;115:209–18.PubMedGoogle Scholar
  2. 2.
    Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol and Hepatol. 2010;7:425–36.CrossRefGoogle Scholar
  3. 3.
    Fallowfield JA. Therapeutic targets in liver fibrosis. Am J Physiol-Gastrointest Liver Physiol. 2011;300:G709–15.PubMedCrossRefGoogle Scholar
  4. 4.
    Kawada N. Evolution of hepatic fibrosis research. Hepatol Res. 2011;41:199–208.PubMedCrossRefGoogle Scholar
  5. 5.
    Saile B, Ramadori G. Inflammation, damage repair and liver fibrosis—role of cytokines and different cell types. Z Gastroent. 2007;45:77–86.CrossRefGoogle Scholar
  6. 6.
    Pinzani M, Macias-Barragan J. Update on the pathophysiology of liver fibrosis. Expert Rev Gastroenterol Hepatol. 2010;4:459–72.PubMedCrossRefGoogle Scholar
  7. 7.
    O’Neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol. 2003;3:396–403.PubMedCrossRefGoogle Scholar
  8. 8.
    Zhu JK, Mohan C. Toll-like receptor signaling pathways-therapeutic opportunities. Mediat Inflamm. 2010. Art ID 781235.Google Scholar
  9. 9.
    Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract. 2010. Art ID 192543.Google Scholar
  10. 10.
    Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, et al. Endotoxemia in patients with chronic liver-diseases—relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol. 1995;22:165–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Parlesak A, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 2000;32:742–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Choi Y, Jeon WK, Hwang SJ, Kim BI, Sohn CI, Park DI, et al. The Role of the Gut Barrier Function in the Pathophysiology of Viral Liver Cirrhosis. Hepato-Gastroenterol. 2011;58:1244–7.Google Scholar
  13. 13.
    Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008;48:322–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Brun P, Castagliuolo I, Pinzani M, Palu G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol-Gastroint Liver Physiol. 2005;289:G571–8.CrossRefGoogle Scholar
  15. 15.
    Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003;37:1043–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Thirunavukkarasu C, Watkins SC, Gandhi CR. Mechanisms of endotoxin-induced NO, IL-6, and TNF-alpha production in activated rat hepatic stellate cells: role of p38 MAPK. Hepatol. 2006;44:389–98.CrossRefGoogle Scholar
  17. 17.
    Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Feng RT, Lu YJ, Bowman LL, Qian Y, Castranova V, Ding M. Inhibition of activator protein-1, NF-kappa B, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem. 2005;280:27888–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang X, Huang H, Yang TT, Ye Y, Shan JH, Yin ZM, et al. Chlorogenic acid protects mice against lipopolysaccharide-induced acute lung injury. Inj Int J Care Inj. 2010;41:746–52.Google Scholar
  20. 20.
    Kono Y, Kobayashi K, Tagawa S, Adachi K, Ueda A, Sawa Y, et al. Antioxidant activity of polyphenolics in diets Rate constants of reactions of chlorogenic acid and caffeic acid with reactive species of oxygen and nitrogen. Biochim Biophys Acta. 1997;1335:335–42.PubMedCrossRefGoogle Scholar
  21. 21.
    Shi HY, Dong L, Bai YH, Zhao JH, Zhang Y, Zhang L. Chlorogenic acid against carbon tetrachloride-induced liver fibrosis in rats. Eur J Pharmacol. 2009;623:119–24.PubMedCrossRefGoogle Scholar
  22. 22.
    Xu YX, Chen JW, Yu XA, Tao WW, Jiang FR, Yin ZM, et al. Protective effects of chlorogenic acid on acute hepatotoxicity induced by lipopolysaccharide in mice. Inflamm Res. 2010;59:871–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Shan JH, Fu J, Zhao ZH, Kong XQ, Huang H, Luo L, et al. Chlorogenic acid inhibits lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells through suppressing NF-kappa B and JNK/AP-1 activation. Int Immunopharmacol. 2009;9:1042–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang BB, Cheng JY, Gao HH, Zhang Y, Chen ZN, Bian HJ. Hepatic stellate cells in inflammation-fibrosis-carcinoma axis. Anat Rec. 2010;293:1492–6.CrossRefGoogle Scholar
  25. 25.
    Vogel S, Piantedosi R, Frank J, Lalazar A, Rockey DC, Friedman SL, et al. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res. 2000;41:882–93.PubMedGoogle Scholar
  26. 26.
    Lebel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2′, 7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol. 1992;5:227–31.PubMedCrossRefGoogle Scholar
  27. 27.
    Choi HK, Pokharel YR, Lim SC, Han HK, Ryu CS, Kim SK, et al. Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-beta 1 expression. Toxicol Appl Pharmacol. 2009;240:377–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radical Biol Med. 2010;48:1121–32.CrossRefGoogle Scholar
  29. 29.
    Wu J, Meng ZJ, Jiang M, Zhang EJ, Trippler M, Broering R, et al. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology. 2010;129:363–74.PubMedCrossRefGoogle Scholar
  30. 30.
    Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–51.PubMedCrossRefGoogle Scholar
  31. 31.
    DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 1997;388:548–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The I kappa B kinase complex (IKK) contains two kinase subunits, IKK alpha and IKK beta, necessary for I kappa B phosphorylation and NF-kappa B activation. Cell. 1997;91:243–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol. 1998;152:423–30.PubMedGoogle Scholar
  34. 34.
    Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin Liver Dis. 2010;30:215–25.PubMedCrossRefGoogle Scholar
  35. 35.
    Seki E, De Minicis S, Inokuchi S, Taura K, Miyai K, Van Rooijen N, et al. CCR2 Promotes Hepatic Fibrosis in Mice. Hepatology. 2009;50:185–97.PubMedCrossRefGoogle Scholar
  36. 36.
    Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology. 1999;29:140–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Tsuruta S, Nakamuta M, Enjoji M, Kotoh K, Hiasa K, Egashira K, et al. Anti-monocyte chemoattractant protein-1 gene therapy prevents dimethylnitrosamine-induced hepatic fibrosis in rats. Int J Mol Med. 2004;14:837–42.PubMedGoogle Scholar
  38. 38.
    Kayano K, Okita K. Does IL-6 regulate liver fibrosis/cirrhosis directly and indirectly? J Gastroenterol. 2000;35:250–1.PubMedCrossRefGoogle Scholar
  39. 39.
    Choi I, Kang HS, Yang Y, Pyun KH. IL-6 induces hepatic inflammation and collagen-synthesis in vivo. Clin Exp Immunol. 1994;95:530–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappaB. J Immunol. 2004;172:2522–9.PubMedGoogle Scholar
  41. 41.
    Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappaB. J Immunol. 2004;173:3589–93.PubMedGoogle Scholar

Copyright information

© Springer Basel 2013

Authors and Affiliations

  • Haitao Shi
    • 1
  • Lei Dong
    • 1
  • Xiaoyan Dang
    • 1
  • Yaping Liu
    • 1
  • Jiong Jiang
    • 1
  • Yan Wang
    • 1
  • Xiaolan Lu
    • 1
  • Xiaoyan Guo
    • 1
  1. 1.Department of GastroenterologySecond Affiliate Hospital of Xi’an Jiao Tong UniversityXi’anChina

Personalised recommendations